Are beta-blockers useful in the prevention of osteoporotic fractures?

European Review for Medical and Pharmacological Sciences

Volumn 13, Issue 3, 2009, Pages 157-162

  Pérez Castrillón, José Luis ^a,b   De Luis, D A ^a,b   Duenas Laita, A ^a  

^a HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^b Rio Hortega University Hospital ^*  (Spain)

Author keywords

Atherosclerosis; Beta blockers; Fractures; Osteoporosis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE BETA MONOOXYGENASE; ESTROGEN; INTERLEUKIN 1; INTERLEUKIN 6; PARATHYROID HORMONE; RALOXIFENE; SEX HORMONE; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

ATHEROSCLEROSIS; BONE DENSITY; BONE MASS; BONE REMODELING; CATECHOLAMINE RELEASE; CHRONIC DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; FRACTURE; HEART FAILURE; HUMAN; HYPERTENSION; MORTALITY; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PREVALENCE; RECEPTOR BINDING; REVIEW; RISK REDUCTION; TREATMENT INDICATION;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 68349109498     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. HOFBAUER LC, BRUECK CC, SHANAHAN CM, SCHOPPER M, DOBNIG H. Vascular calcification and osteoporosis, from clinical observation towards molecular understanding. Osteoporosis Int 2007; 18: 251-259.
2. BAGGER YZ, RASMUNSSEN HB, ALEXANDERSEN P, WERGE T, CHRISTIANSEN C, TANKÓ LB. Links between cardiovascular disease and osteoporosis in postmenopausal women: serum lipids or atherosclerosis per se? Osteoporosis Int 2007; 18: 505-512.
3. HANSSON GK. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
4. MAGNUS JH, BROUSSARD DL. Relationship between BMD and myocardial infarction in US adults. Osteoporos Int 2005; 16: 2053-2062. (Pubitemid 41790927)
5. PÉREZ-CASTRILLON JL, ABAD L, VEGA G, SANZ-CANTALAPIEDRA A, SAN MIGUEL A, MAZÓN A, DE LUIS D, DUEÑAS-LAITA A. Bone mineral density, bone remodelling and osteoprotegerin in patients with acute coronary syndrome. Int J Cardiol 2008; 129: 144-145.
6. KENNY AM, BOXER R, WALSH S, HAGER WD, RAISZ LG. Femoral BMD in patients with heart failure. Osteoporos Int 2006; 17: 1420-1427.
7. SENNERBY U, FARAHMAND B, AHLBOM A, LJUNGHALL S, MICHAËLSSON K. Cardiovascular diseases and future risk of hip fracture in women. Osteoporos Int 2007; 18: 1355-1362. (Pubitemid 47389467)
8. TANKÓ LB, CHRISTIANSEN C, COX DA, GEIGER MJ, MCNABB MA, CUMMINGS SR. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 2005; 20: 1912-1920.
9. RAISZ LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005; 115: 3318-3325.
10. ZAIDI M. Skeletal remodelling in health and disease. Nat Med 2007; 13: 792-801.
11. GONZALEZ-MACIAS J, OLMOS MARTINEZ JM. Fisiopatologia de la osteoporosis. Medicine 2006; 9: 1-7.
12. KARSENTY G. Convergence between bone and energy homeostases: review leptin regulation of bone mass. Cell Metabolism 2006; 4: 341-348. (Pubitemid 44645074)
13. BELTOWSKI J. Leptin and atherosclerosis. Atherosclerosis 2006; 189: 47-60.
14. DUCY P, AMLING M, TAKEDA S, PRIEMEL M, SCHILLING AF, BEIL FT, SHEN J, VINSON C, RUEGER JM, KARSENTY G. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000; 100: 197-207.
15. TAKEDA S, ELEFTERIOU F, LEVASSEUR R, LIU X, ZHAO L, PARKER KL, ARMSTRONG D, DUCY P, KARSENTY G. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002; 111: 305-317.
16. BENAVIC JL, BOUVIER M, COREN MG, LEFKOWITZ RJ. Regulation of adenyl ciclase-coupled beta adrenergic receptors. Annu Rev Cell Biol 1988; 4: 405-428.
17. TOGARI A, ARAI M, MIZUMATI S, KOSHIHARE Y, NAGATSU T. Expression of mRNAs for neuropeptide receptors and beta-adrenergic receptors in human osteoblasts and human osteosarcoma cells. Neurosci Lett 1997; 233: 125-128.
18. BONNET N, BENHAMOU CL, BRUNET-IMBAULT B, ARLETTAZ A, HORCAJADA MN, RICHARD O, VICO L, COLLOMP K, COURTEIX D. Severe bone alterations under beta2 agonist treatments: bone mass, microarchitecture and strength analyses in female rats. Bone 2005; 37: 622-633.
19. FU L, PATEL MS, BRADLEY A, WAGNER EF, KARSENTY G. The molecular clock mediates leptin-regulated bone formation. Cell 2005; 122: 803-815.
20. ELEFTERIOU F, TAKEDA S, EBIHARA K, MAGRE J, PATANO N, KIM CA, OGAWA Y, LIU X, WARE SM, CRAIGEN WJ, ROBERT JJ, VINSON C, NAKAO K, CAPEAU J, KARSENTY G. Serum leptin level is a regulator of bone mass. Proc Natl Acad Sci USA 2004; 101: 3258-3263. (Pubitemid 38327768)
21. ELEFTERIOU F, AHN JD, TAKEDA S, STARBUCK M, YANG X, LIU X, KONDO H, RICHARDS WG, BANNON TW, NODA M, CLEMENT K, VAISSE C, KARSENTY G. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005; 434: 514-520.
22. SANDBERG WJ, YNDESTAD A, ØIE E, SMITH C, UELAND T, OVCHINNIKOVA O, ROBERTSON AK, MÜLLER F, SEMB AG, SCHOLZ H, ANDREASSEN AK, GULLESTAD L, DAMÁS JK, FRØLAND SS, HANSSON GK, HALVORSEN B, AUKRUST P. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 2006; 26: 857-863.
23. PASCO JA, HENRY MJ, SANDERS KM, KOTOWICZ MA, SEEMAN E, NICHOLSON GC. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J Bone Miner Res 2004; 19: 19-24.
24. SCHLIENGER RG, KRAENZLIN ME, JICK SS, MEIER CR. Use of β-blockers and risk of fractures. JAMA 2004; 292: 1326-1332.
25. DE VRIES F, SOUVEREIN PC, COOPER C, LEUFKENS HCM, VAN STAA TP. Use of β-blockers and the risk of hip/femur fracture in the United Kingdom and the Netherlands. Calcif Tissue Int 2007; 80: 69-75. (Pubitemid 46294972)
26. REJNMARK L, VESTERGAARD P, MOSEKILDE L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nation wide case-control study. J Hypertens 2006: 24: 581-589.
27. SCHOO M, STURKENBOOM M, VAN LEEUWEN J, STRICKER B, POLS H. Use of beta-blockers is associated with BMD and fracture risk. Bone 2005; 36 S2: 129-130.
28. BONNET N, GADOIS C, MCCLOSKEY E, LEMINEUR G, LESPESSAILLES E, COURTEIX D, BENHAMOU CL. Protective effect of beta blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture. Bone 2007; 40: 1209-1216.
29. REJNMARK L, VESTERGAARD P, KASSEM M, CHRISTOFFERSEN BR, KOLTHOFF N, BRIXEN K, MOSEKILDE L. Fracture risk in perimenopausal women treated with beta-blockers. Calcif Tissue Int 2004; 75: 365-372.
30. LAVASSEUR R, MARCELLI C, SABATIER JP, DARGENT-MOLINA P. Beta-blocker use, bone mineral density and fracture risk in older women: results from the Epidemiologie de L'Osteoporose Prospective Study. J Am Geriatr Soc 2005; 53: 550-552.
31. REID IR, GAMBLE GD, GREY AB, BLACK DM, ENSRUD KE, BROWNER WS, BAUER DC. Beta-blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 2005; 20: 613-618. (Pubitemid 40393069)
32. MEISINGER C, HEIER M, LANG O, DÖRING A. Beta-blocker use and risk of fractures in men and women from the general population: the MONICA/KORA Augsburg cohort study. Osteoporos Int 2007; 18: 1189-1195. (Pubitemid 47300270)
33. LYNN H, KWOK T, WONG SYS, WOO J, LEUNG PC. Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly chinese. Bone 2006; 38: 584-588.
34. TURKER S, KARATOSUN V, GUNAL I. Beta-blockers increase bone mineral density. Clin Orthop Relat Res 2006; 443: 73-74. (Pubitemid 44324936)
35. PÉREZ-CASTRILLÓN JL, VEGA G, ABAD L, SANZ A, MENDO M, PORRERO MG, DUEÑAS A. Effect of β-blockers on bone mass and biomechanical parameters of the femoral neck in males with acute myocardial infarction. Joint Bone Spine 2007; 74: 259-262.
36. PEREZ-CASTRILLON JL, ABAD L, VEGA G, SANZ-CANTALAPIEDRA A, SAN MIGUEL A, MAZON A et al. Effect of atorvastatin to RANKL/OPG system in patients with acute coronary syndrome. J Appl Res 2005; 5: 569-574. (Pubitemid 44713381)